Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACRL.L Regulatory News (ACRL)

  • There is currently no data for ACRL

Placing Shares Admitted

11 Dec 2017 08:01

RNS Number : 8758Y
Accrol Group Holdings PLC
11 December 2017
 

11 December 2017

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Accrol Group Holdings plc

(AIM: ACRL)

 

Placing Shares Admitted, Appointment of Director

And Total Voting Rights

 

Accrol Group Holdings plc (the "Company" or "Accrol"), the AIM-listed leading independent tissue converter, notes that the 36,000,000 new ordinary shares issued pursuant to the recently announced Placing to raise £18 million have been admitted to trading earlier today ("Admission"). As a consequence, the Revised Banking Facilities and the appointment of Dan Wright as a Director of the Company (each as described in the Company's announcement of 20 November 2017 titled "Proposed Placing of £18m and Lifting of Suspension") are now effective.

 

Peter Cheung, Chairman of Accrol, said: "I would like to take this opportunity to thank all our shareholders, once again, for their support and understanding over the past two months.

 

 "On behalf of all the directors, I am delighted to welcome Dan to the Board. Dan is an experienced operator with considerable knowledge of our business and a strong understanding of the mechanics of the industry and we look forward to working with him."

 

Dan Wright

 

The following information on Dan Wright is required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies:

 

Daniel ("Dan") Patrick Wright, aged 45, is currently a director of the following companies:

 

· NorthEdge Capital I GP LLP

· Waterloo Street BPRA Property Fund LLP

· Vision Support Services Group Limited

· Impulse Partners Limited

· Gomrath Limited

 

In addition, Dan has held the following directorships in the past five years:

 

· Highflex Holdings (UK) Limited (in administration effective 2 August 2017)

· NorthEdge Capital Fund I GP Limited

· NorthEdge Capital Corporate Limited

· NorthEdge Capital Nominee Limited

· NorthEdge Capital Founder GP Limited

· Accrol Group Holdings plc

· Accrol UK Limited

· MP Topco Limited

· Bretherton Barns Limited

· NorthEdge Capital LLP

· Piccadilly Assured Homes Limited

· P. & M.J. Wright (Holdings) Limited

 

Dan is interested in 200,000 Accrol Shares representing 0.16% of the entire issued share capital of Accrol Group Holdings plc.

 

There is no further information on Dan required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

 

Total Voting Rights

 

Following Admission, there are [129,012,002] ordinary shares of £0.01 in the capital of Accrol in issue, with one voting right each. The Company does not hold any shares in treasury. The number of Ordinary Shares with voting rights is therefore [129,012,002]. Accordingly, this number should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

 

Enquiries:

 

Accrol Group Holdings plc Tel: +44 (0) 1254 278 844

Gareth Jenkins, CEO

James Flude, Finance Director

 

Zeus Capital Limited (Nominated Adviser & Broker)

Dan Bate / Andrew Jones Tel: +44 (0) 161 831 1512

Dominic King / John Goold Tel: +44 (0) 203 829 5000

 

Belvedere Communications Limited Tel: +44 (0) 203 567 0510

Cat Valentine (cvalentine@belvederepr.com) Mob: +44 (0) 7715 769 078

Kim van Beeck (kvbeeck@belvederepr.com) Mob: +44 (0) 7477 967 446

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
POSUWONRBRAURAA
Date   Source Headline
27th Jan 20231:27 pmRNSTR-1
24th Jan 20237:00 amRNSHalf Year Results
24th Jan 20237:00 amRNSStrategic Review Outcomes
11th Jan 20237:00 amRNSNotice: Results, Strategic Review & Presentations
20th Dec 20227:00 amRNSDirector Dealing
28th Nov 20221:36 pmRNSLaunch of second ESG Report
21st Nov 20227:00 amRNSHalf Year Trading Update
18th Nov 20227:00 amRNSAwards under LTIP and PDMR dealing
18th Oct 20221:27 pmRNSResult of 2022 Annual General Meeting
23rd Sep 20227:38 amRNSNotice of AGM and Posting of Annual Report 2022
20th Sep 20224:41 pmRNSSecond Price Monitoring Extn
20th Sep 20224:36 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSAudited Final Results
10th Aug 20227:00 amRNSNotice of Final Results and Online Presentations
31st May 202212:21 pmRNSTR-1
17th May 20227:00 amRNSTrading Update - FY22 in line with expectations
10th May 202211:57 amRNSTR-1
7th Apr 20227:00 amRNSTR-1
15th Mar 20223:58 pmRNSTR-1
14th Mar 20227:00 amRNSUpdate on LTC Share Purchase Agreement
11th Mar 20224:41 pmRNSSecond Price Monitoring Extn
11th Mar 20224:36 pmRNSPrice Monitoring Extension
4th Mar 20227:00 amRNSDirector Dealing
24th Feb 20223:45 pmRNSTR-1
24th Feb 20227:00 amRNSAwards under LTIP and PDMR dealing
11th Feb 202212:40 pmRNSTR-1
3rd Feb 20221:59 pmRNSTR-1
2nd Feb 202211:08 amRNSTR-1
21st Jan 20222:42 pmRNSTR-1
18th Jan 20227:00 amRNSHalf Year Results
17th Jan 20226:18 pmRNSTR-1
17th Jan 20223:13 pmRNSTR-1
12th Jan 20227:00 amRNSTrading Update
16th Dec 20217:00 amRNSNotice of Results and Online Investor Presentation
20th Oct 20217:00 amRNSTrading Update
28th Sep 20219:46 amRNSLaunch of ESG Report
24th Sep 202111:59 amRNSResult of AGM
27th Aug 20211:32 pmRNSNotice of AGM and Posting of Annual Report 2021
28th Jul 20215:30 pmRNSTR-1
23rd Jul 20212:35 pmRNSDirector Share Purchase
23rd Jul 20212:31 pmRNSExercise of Options, Director Dealings and TVR
16th Jul 20214:37 pmRNSDirector Shareholding
14th Jul 20217:00 amRNSAudited Final Results
7th Jul 20217:00 amRNSNotice of Results and Online Investor Presentation
4th Jun 202110:38 amRNSTR-1
18th May 20214:41 pmRNSSecond Price Monitoring Extn
18th May 20214:36 pmRNSPrice Monitoring Extension
18th May 20212:06 pmRNSSecond Price Monitoring Extn
18th May 20212:00 pmRNSPrice Monitoring Extension
18th May 202111:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.